Entities / Company
Knight Therapeutics.
Canadian pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 9
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America.Some support1 report1 development inside
-
Knight Therapeutics launched TAVALISSE for chronic ITP treatment and began expanding its presence through regional agreements in Latin America.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Knight Therapeutics this week
News at the entities that move Knight Therapeutics most-
Incyte StructuralIncyte is scheduled to present research data at the European Society for Medical Oncology (ESMO) congress in Madrid.Moves Knight Therapeutics
-
Latin America StructuralJetour is exploring local cultures across Oceania, Europe, and Latin America.Moves Knight Therapeutics
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada, Bank of America, and Morgan Stanley issued various rating and price target updates.Moves Knight Therapeutics
-
Montreal Shared contextTargets agreed upon at a summit in Montreal are currently undergoing assessment.Moves Knight Therapeutics
Connections
The 5 strongest of 9, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Incyte Structural
Knight Therapeutics holds exclusive distribution rights for Incyte's products, forming a co-development and supply partnership.
-
Latin America Structural
Knight Therapeutics is establishing a formal presence and commercializing products through subsidiaries within the Latin America region.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada issued a restated 'outperform' rating on the shares of Knight Therapeutics.
-
Montreal Shared context
Knight Therapeutics is headquartered in the city of Montreal, Canada.
-
Kyowa Kirin Mentioned together
No direct relationship between Knight Therapeutics and Kyowa Kirin was observed in the provided evidence.
History
Events by the month they beganJuly 2026
1 eventJune 2026
3 events- Knight's affiliate submitted an application to ANVISA and secured exclusive distribution rights for Incyte's tafasitamab.
- The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America.
- Knight Therapeutics launched TAVALISSE for chronic ITP treatment and began expanding its presence through regional agreements in Latin America.